Publications by authors named "B G Challis"
Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy.
Clin Transl Radiat Oncol
January 2025
Background: Nodal only recurrence post radical prostatectomy (RP) is increasingly recognised in the PSMA scan era. Management is controversial with a curative approach usually incorporating prostate bed and nodal irradiation (PB + NRT) in combination with long-term hormonal therapy. It is unknown whether omitting prostate-bed irradiation (PBRT) is safe in a subgroup of these patients.
View Article and Find Full Text PDFWe characterized the longitudinal serum protein signatures of women 6 and 10 years after gestational diabetes mellitus (GDM) to identify factors associated with the development of type 2 diabetes mellitus (T2D) and prediabetes in this at-risk post-GDM population, aiming to discover potential biomarkers for early diagnosis and prevention of T2D. Our study identified 75 T2D-associated serum proteins and 23 prediabetes-associated proteins, some of which were validated in an independent T2D cohort. Machine learning (ML) performed on the longitudinal proteomics highlighted protein signatures associated with progression to post-GDM diabetes.
View Article and Find Full Text PDFArticle Synopsis
- Inflammation plays a key role in diabetes-related kidney disease (DKD), affecting patient health and longevity, though the exact mechanisms remain unclear.
- Researchers studied proinflammatory cytokines in DKD patients and mouse models, focusing on the IL-33 pathway and its potential as a treatment target.
- Initial results suggest that inhibiting IL-33 could reduce kidney damage and inflammation, with ongoing clinical trials (FRONTIER-1) exploring a monoclonal antibody treatment for DKD patients.
Background & Aims: Cotadutide, a peptide co-agonist at the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, has demonstrated robust improvements in body weight, glycemia, and hepatic fat fraction (HFF) in patients living with obesity and type 2 diabetes mellitus.
Methods: In PROXYMO, a 19-week randomized double-blind placebo-controlled trial, the safety and efficacy of cotadutide (600 μg, 300 μg) or placebo were evaluated in 74 participants with biopsy-proven noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Analyses were performed using intent-to-treat and modified intent-to-treat population data.